To study clinical efficacy of Zhennaoning capsules in treating cases with cerebral arteriosclerosis, and analyze its economic benefits. Totally 254 cases with cerebral arteriosclerosis were randomly divided into two groups according to their doctor-consulting sequence: the test group (n = 128) that was administered with Zhennaoning capsules, and the control group (n = 126) that was administered with Yangxueqingnao granules. A double-blind parallel-controlled study was conducted for four weeks, in order to observe the clinical efficacy and adverse effects of the two groups, and evaluate their pharmacoeconomics. Additionally, the clinical efficacy and safety of Zhennaoning capsules in treating cerebral arteriosclerosis, as well as its pharmacoeconomics were also discussed. This study showed that Zhennaoning capsules had a better efficacy than its control drug Yangxueqingnao granules in relieving traditional Chinese medicinal syndromes (according to traditional Chinese medicinal syndrome coring, efficacy and cure rate), suggesting a statistical significance (P < 0.01). Despite statistical significance showed from the differences in the remaining indexes and the occurrence rate of adverse effects, the test group displayed a lower cost effectives than the control group (P < 0.01). Zhennaoning capsules have a better clinical efficacy in treating cases with cerebral arteriosclerosis than Yangxueqingnao granules, demonstrating safe clinical application and better economic advantages.

目的观察镇脑宁胶囊治疗偏头痛、紧张性头痛的临床疗效。方法将300例偏头痛及268例紧张性头痛患者随机分为2组:治疗组280例给予镇脑宁胶囊1.2 g口服3次/d;对照组288例给予正天丸6 g口服3次/d,比较2组临床疗效。结果治疗组疗效显著,头痛月发作次数、发作持续时间、VAS评分及中医证候疗效均显著优于对照组。结论镇脑宁胶囊治疗偏头痛和紧张性头痛疗效显著。

Objective To investigate the compatible stability of cefoxintin sodium for injection and Yinzhihuang Injection(a compound injection of Chinese materia medica) in 5% glucose injection.Methods high performance liquid chromatography(HPLC) was established for the quantitative determination of cefoxintin and baicalin within 4 h after the compatibility of cefoxintin sodium for injection and Yinzhihuang Injection,and the changes of solution color,pH value,and insoluble particles were observed.Results The solution color and pH value showed no obvious changes.But the contents of cefoxintin and baicalin as well as the insoluble particles were increased with the compatible time extending.Conclusion The solution is unstable within 4 h after the compatibility of cefoxintin sodium for injection and Yinzhihuang Injection.So it should not be used in the compatibility.

Objective To evaluate the clinical efficacy and safety of Zhennaoning Capsule(ZC) in the treatment of hypertension headache and to evaluate its pharmacoeconomics.Methods The patients(243 cases) with hypertension headache were randomly divided into the treatment(120 cases) and control(123 cases) groups.The patients in the treatment group were po administered with ZC,4 capsules once,three times daily,and at the same time,they were po administered with Yangxue Qingnao Granules(YQG)simulated agent,1 bag once,three times daily.Patients in the control group were po administered with YQG,1 bag once,three times daily,and at the same time,they were po administered with ZC simulated agent,4 capsules once,three times daily.All the patients continued taking antihypertensive drugs,but the Chinese materia medica for hypertension headache and kidney yin dificiency were prohibited.The course of the treatment was eight weeks,and the single-blind and parallel-controlled contrast studies were adopted.The clinical efficacy and safety of the two groups were observed and evaluated by the cost-effectiveness method of pharmacoeconomics.Results There were no differences between the two groups on the clinical efficacy and safety,but the cost-effectiveness of the treatment group was lower than that of the control group(P<0.01).Conclusion Compared with YQG,ZC is better in the treatment of hypertension headache.The therapeutic effect is reliable and safe and has more obvious economic advantages.

目的研究红花注射液与头孢西丁钠的配伍稳定性。方法在模拟临床用药浓度条件下,采用高效液相色谱法测定红花注射液与头孢西丁钠配伍后4 h内羟基红花黄色素A和头孢西丁的含量,考察配伍液外观、pH值、不溶性微粒的变化。结果 4 h内配伍液的外观、pH值、二者的含量均无明显改变,不溶性微粒数随着时间的延长逐渐增多,仍符合药典标准。结论红花注射液与头孢西丁钠配伍后4 h内稳定。

目的探讨妊娠梅毒孕期正规抗梅毒治疗对分娩结局的影响。方法产前检查118例经实验室血清学确诊为妊娠梅毒孕产妇,根据妊娠期是否接受抗梅毒正规治疗分为治疗组(68例)及对照组(未治疗组50例),比较2组孕产妇的妊娠结局、围生儿预后及新生儿先天梅毒的发生情况。结果治疗组足月分娩率、早产率及死产、死胎率与对照组相比较有显著性差异(P均<0.01)。治疗组先天性梅毒患儿发生率与对照组比较有显著性差异(P<0.01)。结论孕期应常规开展梅毒血清学的筛查工作以早期发现,有效的抗梅毒治疗是改善妊娠梅毒患者妊娠结局以及降低先天性梅毒患儿发生率的关键。

Objective:To investigate the compatible stability of danshen dripping solution and cefoxintin sodium.Method: The content of sodium danshensu,protocatechualdehyde and cefoxintin were determined after compatibility of danshen dripping solution and cefoxintin sodium within 4 hours by HPLC,and the changes of solution color,pH value and insoluble particles were observed in the simulation conditions of clinical concentration.Result: The solution color and pH value showed no obvious changes.The number of insoluble particles was increased and the content of sodium danshensu,protocatechualdehyde and cefoxintin were reduced with the extending of compatible time.Conclusion: The solution was unstable after compatibility of danshen dripping solution and cefoxintin sodium within 4 hours,therefore,not suggesting to compatibility use.